LENZ Therapeutics, Inc. (LENZ) Cash Flow Statement
LENZ Therapeutics, Inc. (LENZ) generated -$113.9M of operating cash flow over the twelve months to 2026-06-30, spent $511000 on capital expenditure and had free cash flow of -$114.4M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LENZLENZ Therapeutics, Inc.Follow LENZ — free
—
Price chart with a free account
- Market cap
- 99.3M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 29 Oct, in 5 days
| Line | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|
| Operating cash flow | -69.2 | -113.9 | |
| Capital expenditure | 0.8 | -0.5 | |
| Free cash flow | -70.0 | -114.4 | |
| Stock-based compensation | 12.5 | — |
USD millions · SEC XBRL
LENZ Therapeutics, Inc. — questions
- What is LENZ Therapeutics, Inc.'s operating cash flow?
- -$113.9M over the twelve months to 2026-06-30.
- How much does LENZ Therapeutics, Inc. spend on capital expenditure?
- $511000 over the twelve months to 2026-06-30.
- What is LENZ Therapeutics, Inc.'s free cash flow?
- -$114.4M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from LENZ Therapeutics, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.